drugset / Trial / NCT05691400
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The objective of this study is to estimate the effect of CYP3A4\*22 on the clearance and area under the plasma concentration-time curve of Palbociclib, Ribociclib, and Abemaciclib
Timeline
- Start
- 2024-03
- Primary completion
- 2027-03
- Completion
- 2027-03
Outcome
Outcome not reported
Stopped (Business): “funding was not secured”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Ribociclib | Small molecule | 200 mg | Oral |